Gabather AB — Investor Relations & Filings

Gabather AB is a pharmaceutical company developing next-generation therapeutics for neuropsychiatric and other Central Nervous System (CNS) disorders. The company's approach focuses on restoring brain balance by targeting the GABAA receptor system. Its proprietary drug candidates aim to enhance cognitive function. The lead candidate, GT-002, has completed Phase I clinical trials, demonstrating a favorable safety and tolerability profile. Gabather's development program targets major unmet medical needs across four key areas: anti-psychotics, anti-depressants/anxiolytics, analgesics, and cognition-enhancing treatments for conditions such as Schizophrenia and Alzheimer's disease.